EE330 Economic Burden of Biologic Therapy for Chinese Patients with Crohn's Disease
This study aimed to evaluate the economic burden of vedolizumab, infliximab and its biosimilars, adalimumab and its biosimilars, and ustekinumab for Crohn ’s disease (CD) patients from Chinese societal perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Y. Sheng, Y. Hu Source Type: research
Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients
This study evaluated the approval time for biologics in IBD.METHODS: A chart review of IBD patients seen in a university gastroenterology clinic over 5 years was performed. Patient gender, race, IBD subtype, biologic use, and insurance type were recorded. Insurance type was classified as private or public (Medicaid or Medicare). Biologic agents evaluated included infliximab, adalimumab, vedolizumab and ustekinumab. Length of time to approval (TTA) and length of time to first infusion or administration (TFI) were recorded. Analysis was performed using t-testing, Fisher's exact testing, and ANOVA with significance set at p&l...
Source: Journal of the National Medical Association - November 30, 2023 Category: General Medicine Authors: Vinay Rao Ishaan Dharia Jessica Gibilisco Danielle Kirelik Scott Baumgartner Katherine Negreira Karan Chawla Jenny Dave Samuel Kallus Omar Ali Belfaqeeh Marie L Borum Source Type: research
Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan
ConclusionTreatment modification of IL-inhibitors for PsO was commonly observed and could indicate insufficient disease control and/or incremental economic burden. Discontinuation and switching rates were lowest for RIS regardless of time point and adjustment for patient characteristics. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - November 29, 2023 Category: Dermatology Source Type: research
Role of ustekinumab in treatment of ulcerative colitis: a narrative review
Immunotherapy, Ahead of Print. (Source: Immunotherapy)
Source: Immunotherapy - November 29, 2023 Category: Allergy & Immunology Authors: Mauro Grova Alessandro Vitello Mariella Mannino Angelo Cas à Sara Renna Fabio Salvatore Macaluso Ambrogio Orlando Source Type: research
Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis
CONCLUSIONS: Given the results suggesting shorter sustainability, the need for earlier intensification and thus higher drug exposure, and the greater need for immunosuppression with infliximab than with adalimumab, the choice of these drugs cannot be considered completely equitable.IMPACT: Our study identified predictors of sustainability of biologic treatment in paediatric patients with Crohn's disease, including adalimumab (versus infliximab), early initiation of biologic treatment, and normalised baseline haemoglobin levels. Infliximab treatment was associated with earlier intensification, higher drug exposure, and a gr...
Source: Pediatric Research - November 27, 2023 Category: Pediatrics Authors: Ondrej Hradsky Ivana Copova Marianna Durilova Denis Kazeka Tereza Lerchova Katarina Mitrova Jan Schwarz Romana Vetrovcova Nabil El-Lababidi Eva Karaskova Maria Veghova-Velganova Astrid Sulakova Lucie Gonsor číková Marketa Veverkova Ivana Zeniskova Mart Source Type: research
Use of real-world data to assess the effectiveness of ustekinumab in treating IBD patients: a retrospective linked database study in northwest London
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - November 27, 2023 Category: Drugs & Pharmacology Authors: Nik KamperidisMoulesh ShahSophie YoungEvgeniy GalimovShruti SweeneyNaila Arebia Department of Gastroenterology, St Marks Hospital, London, UKb Imperial College Health Partners, London, UKc Janssen Cilag Limited, High Wycombe, UK Source Type: research
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
ConclusionsCT-P43 demonstrated equivalent efficacy to originator ustekinumab in patients with moderate to severe plaque psoriasis, with comparable pharmacokinetic, safety and immunogenicity profiles.Clinical Trial RegistrationClinicalTrials.gov Identifier: NCT04673786; date of registration: 17 December, 2020 (Source: BioDrugs)
Source: BioDrugs - November 22, 2023 Category: Drugs & Pharmacology Source Type: research
Variation in access and prescription of vedolizumab and ustekinumab in paediatric patients with inflammatory bowel disease: a UK-wide study
Conclusions
There is widespread use of vedolizumab and ustekinumab across the UK, although practice is highly variable. Access to therapy appeared to differ substantially. There is a growing disparity between international guidelines and real-world practice. Establishing early and effective therapy in all patients remains a priority. (Source: Archives of Disease in Childhood)
Source: Archives of Disease in Childhood - November 17, 2023 Category: Pediatrics Authors: Auth, M. K.-H., Ashton, J. J., Jones, K. D. J., Rodrigues, A., Thangarajah, D., Devadason, D., Lee, G., Ayaz, M., Lee, H. M., Kammermeier, J., BSPGHAN IBD Biologics Survey Contributors, Lee, Swann, Garrick, Torrente, Deb, Doble, Paul, Coelho, Zamvar, Naru Tags: Original research Source Type: research
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort
CONCLUSIONS: Ustekinumab demonstrated, in the real-world setting, long-term effectiveness and a favorable safety profile in a cohort of refractory UC patients.PMID:37933161 | DOI:10.1080/00365521.2023.2278427 (Source: Scandinavian Journal of Gastroenterology)
Source: Scandinavian Journal of Gastroenterology - November 7, 2023 Category: Gastroenterology Authors: Marisa Iborra Rocio Ferreiro-Iglesias Mart ín-Arranz Maria Dolores Francisco Mesonero Gismero Alejandro M ínguez Sol Porto-Silva Laura Garc ía-Ramírez Irene Garc ía de la Filia Mariam Aguas Laura Nieto-Garc ía Cristina Su árez Ferrer Guillermo Bast Source Type: research
Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease
We report a case of dual biologic therapy with ustekinumab and dupilumab in a patient with severe Crohn disease and atopic dermatitis. There was no interference between these drugs after a 7-month follow-up.PMID:37929636 | DOI:10.1111/ajd.14185 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Alberto Alegre-Bailo Araceli S ánchez-Gilo In és Gonzalo González Francisco Javier Vicente Mart ín Source Type: research
Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease
We report a case of dual biologic therapy with ustekinumab and dupilumab in a patient with severe Crohn disease and atopic dermatitis. There was no interference between these drugs after a 7-month follow-up.PMID:37929636 | DOI:10.1111/ajd.14185 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - November 6, 2023 Category: Dermatology Authors: Alberto Alegre-Bailo Araceli S ánchez-Gilo In és Gonzalo González Francisco Javier Vicente Mart ín Source Type: research
